Clinical Research Method for the Fast, Efficient Analysis of Mycophenolic Acid Utilizing Online Solid-Phase Extraction in Conjunction with UPLC/MS/MS

Significance of the Topic

A rapid, automated assay for mycophenolic acid is vital in therapeutic drug monitoring of transplant patients. High sensitivity and selectivity improve dosing accuracy and patient outcomes.

Objectives and Study Overview

This study aimed to integrate online solid phase extraction with ultra performance liquid chromatography tandem mass spectrometry for efficient measurement of mycophenolic acid in human plasma. The method was benchmarked against existing LC/MS/MS workflows.

Methodology and Instrumentation

• Sample Preparation: Protein precipitation of 50 µL plasma with zinc sulfate and deuterated internal standard, followed by centrifugation and transfer to a 96-well plate.
• Online SPE: Waters MassTrak Online SPE Analyzer with XBridge C18 cartridges. Steps included methanol conditioning, water equilibration, sample loading, wash with 25% methanol, elution via UPLC gradient, and parallel cartridge operation to maximize throughput.
• Chromatography: ACQUITY UPLC HSS C18 SB column (2.1×30 mm, 1.8 µm) at 50 °C. Mobile phases of ammonium acetate/formic acid in water and methanol, 0.7 mL/min flow, 2.5 min total runtime.
• Mass Spectrometry: ACQUITY TQ Detector in positive ESI MRM mode. Transitions 321.2>207.2 and 321.2>159.2 for mycophenolic acid, 324.2>210.2 for d3-internal standard.
• Data Management: MassLynx v4.1 with TargetLynx application.

Main Results and Discussion

• Retention at 1.47 min with baseline resolution from glucuronide metabolites; injection-to-injection time 3.0 min.
• Full 96-well plate processed in ~5.5 hours.
• Linearity over 0.01–50.0 µg/mL (r2 > 0.996); LOD 2 ng/mL; LOQ 7 ng/mL.
• Intra-assay CVs 9.2–9.6%; inter-assay CVs 5.8–8.4% across QC levels.
• Recoveries between 92% and 116% for spikes at 1.5, 3.0, 6.0 µg/mL.
• Method comparison via Deming regression yielded slope 0.99 and bias 1%; Bland-Altman confirmed agreement.
• No interference from elevated cholesterol, albumin, or co-administered immunosuppressants; negligible ion suppression observed.

Contributions and Practical Applications

The fully automated SPE-UPLC/MS/MS workflow reduces manual handling, increases sample throughput, enhances robustness, and meets stringent clinical laboratory requirements for mycophenolic acid monitoring.

Future Trends and Potential Applications

Anticipated developments include multiplexed panels for immunosuppressants, miniaturized SPE cartridges for faster elution, higher-capacity autosamplers, and integrated software solutions for real-time data review in clinical settings.

Conclusion

This integrated online SPE-UPLC/MS/MS method delivers a sensitive, precise, and high-throughput solution for routine clinical monitoring of mycophenolic acid, offering clear advantages over traditional immunoassays and standalone LC/MS methods.

Reference

1. Vogeser M et al. Therapeutic Drug Monitoring 2001;23(6):722–724
2. CLSI EP-6A Evaluation of Linearity of Quantitative Measurement Procedures 2003
3. CLSI EP07 Interference Testing in Clinical Chemistry 2005